GW Pharmaceuticals PLC- (NASDAQ:GWPH) Shares Bought by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC boosted its holdings in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 9.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,163 shares of the biopharmaceutical company’s stock after acquiring an additional 100 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in GW Pharmaceuticals PLC- were worth $133,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of GWPH. Envestnet Asset Management Inc. grew its stake in GW Pharmaceuticals PLC- by 4.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 2,014 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 92 shares in the last quarter. Close Asset Management Ltd lifted its holdings in shares of GW Pharmaceuticals PLC- by 13.5% in the 2nd quarter. Close Asset Management Ltd now owns 876 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 104 shares during the last quarter. Aperio Group LLC lifted its holdings in shares of GW Pharmaceuticals PLC- by 4.0% in the 2nd quarter. Aperio Group LLC now owns 2,763 shares of the biopharmaceutical company’s stock valued at $476,000 after purchasing an additional 106 shares during the last quarter. D.A. Davidson & CO. lifted its holdings in shares of GW Pharmaceuticals PLC- by 3.3% in the 2nd quarter. D.A. Davidson & CO. now owns 3,611 shares of the biopharmaceutical company’s stock valued at $623,000 after purchasing an additional 117 shares during the last quarter. Finally, Rothschild Investment Corp IL lifted its holdings in shares of GW Pharmaceuticals PLC- by 0.7% in the 2nd quarter. Rothschild Investment Corp IL now owns 17,689 shares of the biopharmaceutical company’s stock valued at $3,049,000 after purchasing an additional 120 shares during the last quarter. 82.89% of the stock is owned by institutional investors and hedge funds.

GWPH opened at $109.41 on Friday. The business has a 50 day moving average price of $122.70 and a two-hundred day moving average price of $154.23. The company has a quick ratio of 7.59, a current ratio of 8.31 and a debt-to-equity ratio of 0.03. The company has a market cap of $4.16 billion, a PE ratio of -10.36 and a beta of 2.28. GW Pharmaceuticals PLC- has a 52 week low of $90.14 and a 52 week high of $196.00.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.74) by $0.96. The firm had revenue of $72.04 million during the quarter, compared to the consensus estimate of $37.28 million. GW Pharmaceuticals PLC- had a negative return on equity of 23.44% and a negative net margin of 26.80%. The firm’s revenue was up 2096.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.25) EPS. As a group, sell-side analysts expect that GW Pharmaceuticals PLC- will post -3.53 EPS for the current fiscal year.

In other GW Pharmaceuticals PLC- news, insider Douglas B. Snyder sold 3,756 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $13.88, for a total transaction of $52,133.28. Following the transaction, the insider now owns 79,164 shares in the company, valued at approximately $1,098,796.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Douglas B. Snyder sold 5,424 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $13.04, for a total value of $70,728.96. Following the transaction, the insider now owns 73,740 shares in the company, valued at approximately $961,569.60. The disclosure for this sale can be found here. 3.60% of the stock is owned by corporate insiders.

Several analysts have recently weighed in on the company. Needham & Company LLC assumed coverage on GW Pharmaceuticals PLC- in a report on Monday, October 21st. They issued a “buy” rating and a $200.00 target price for the company. ValuEngine raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Wednesday, September 4th. BidaskClub downgraded GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reissued a “buy” rating on shares of GW Pharmaceuticals PLC- in a report on Friday. Finally, Zacks Investment Research raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $122.00 target price for the company in a report on Saturday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $198.00.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Read More: Bollinger Bands

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.